Skip to Content

Exact Sciences Corp - Stock Quote EXAS

Rating as of

Morningstar's Exact Sciences Corp Stock Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Upgrading Exact Sciences' Moat Trend to Positive on Improving Liquid Biopsy Pipeline

Aaron Degagne Equity Analyst

Business Strategy and Outlook

| Aaron Degagne |

Exact Sciences has a three-prong approach to cancer testing: non-invasive Cologuard is likely to continue gaining share of colorectal cancer screening, and ongoing development of both early screening and minimum residual disease (MRD) testing gives Exact exposure to the nascent liquid biopsy market. Exact is attempting to position itself as a winner regardless of whether liquid biopsy takes off, with Cologuard likely to remain a decent alternative to colonoscopy over the near term, while the firm’s pan-cancer and single-cancer liquid biopsy tests could offset Cologuard share loss in a scenario where liquid biopsy rapidly gains share.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - EXAS

Exact Sciences Corp's Company Profile

Business Description

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.

Contact
5505 Endeavor Lane
Madison, WI, 53719
T +1 608 284-5700
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 6,500